DNA-based immunotherapeutics for the treatment of allergic disease

Immunological Reviews

Volumn 179, Issue , 2001, Pages 102-118

  Horner, Anthony A ^a   Van Uden, John H ^a   Zubeldia, Jose M ^a   Broide, David ^a   Raz, Eyal ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; DNA; OLIGONUCLEOTIDE;

ALLERGIC DISEASE; ANAPHYLAXIS; COST; DESENSITIZATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INDUSTRIALIZATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANAPHYLAXIS; ANIMALS; ASTHMA; BCG VACCINE; CONJUNCTIVITIS, ALLERGIC; CPG ISLANDS; DESENSITIZATION, IMMUNOLOGIC; DNA; GENETIC VECTORS; HUMANS; HYPERSENSITIVITY; IMMUNOCONJUGATES; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; MICE; MODELS, ANIMAL; MODELS, IMMUNOLOGICAL; OLIGODEOXYRIBONUCLEOTIDES; TH2 CELLS; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0035101984     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2001.790111.x     Document Type: Review

References (72)

1. Forecasted state-specific estimates of self-reported asthma prevalence - United States, 1998
2. The epidemic of allergy and asthma
3. Is allergy increasing? - Early life influences
4. Age of entry to day nursery and allergy in later childhood
5. Measles and atopy in Guinea-Bissau
6. The inverse association between tuberculin responses and atopic disorder
7. Immunotherapy
8. Immunotherapy for aeroallergen disease
9. Responses to ragweed-pollen nasal challenge before and after immunotherapy
10. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract
11. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization
12. Gene immunization for allergic disorders
13. DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice
14. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization
15. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen
16. Isoforms of the major allergen of birch pollen induce different immune responses after genetic immunization
17. A DNA vaccine for allergen immunotherapy using the latex allergen Hev b 5
18. Oral gene delivery with chitosan - DNA nanoparticles generate immunologic protection in a murine model of peanut allergy
19. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
20. Contribution of CpG motifs to the immunogenicity of DNA vaccines
21. Sensitization and antibody formation after injection of tubercule bacilli and paraffin oil
22. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity
23. In vitro augmentation of natural killer cell activity and production of interferon-α/β and -γ with deoxyribonucleic acid fraction from Mycobacterium bovis BCG
24. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity
25. DNA methylation the frequency of CpG in animal DNA
26. CpG motifs in bacterial DNA trigger direct B-cell activation
27. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
28. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
29. Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway
30. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences
31. In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG
32. Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells
33. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
34. Activation of human B cells by phosphorothioate oligodeoxynucleotides
35. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
36. Immunostimulatory DNA is a potent mucosal adjuvant
37. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
38. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
39. Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice
40. Immunostimulatory DNA pre-priming: A novel approach for prolonged Th1-biased immunity
41. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses
42. Pre-priming: A novel approach to DNA-based vaccination and immunomodulation
43. Anaphylaxis
44. Fatal and near-fatal anaphylactic reactions to food in children and adolescents
45. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice
46. Passive anaphylaxis in mice with γ-G antibodies. V. Competitive effects of different immunoglobulins and inhibition of reactions with antiglobulin sera
47. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fcγ/RIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis
48. Active anaphylaxis in IgE-deficient mice
49. Sorting out the cytokines of asthma
50. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma
51. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia
52. Human eosinophils
53. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
54. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever
55. Abrogation of reaginic antibodies with modified allergens
56. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity
57. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity
58. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism
59. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator
60. Immunostimulatory oligodeoxynucleotides conjugated to Amb a 1: Safety, skin test reactivity, and basophil histamine release
61. Prophylactic inoculation against hayfever
62. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
63. CpG motifs as immune adjuvants
64. + T cells into Th1 effectors
65. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-γ production in cells from allergic individuals and inhibit IgE synthesis in vitro
66. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice
67. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides
68. Current concepts in ocular allergy
69. Allergic conjunctivitis
70. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis